Corneal graft rejection – Diagnostics – Overview of Information and Clinical Research

Corneal graft rejection is a specific immune response where the body attacks transplanted corneal tissue, potentially threatening vision and the success of the transplant. Early detection through careful examination and monitoring is crucial for preserving the graft and preventing permanent damage to sight.

Introduction: Who Should Seek Diagnostic Evaluation

Anyone who has received a corneal transplant should be aware that their transplanted cornea requires ongoing monitoring throughout their lifetime. Patients need to understand when to seek diagnostic evaluation urgently. If you have undergone corneal transplantation and experience symptoms such as redness of the eye, decreased vision, pain, or sensitivity to light, you should contact your eye care specialist immediately. These symptoms may indicate that your body is beginning to reject the donor tissue, which is a medical situation requiring prompt attention.^[1]

Regular follow-up examinations are essential even when you feel perfectly fine. Your eye doctor needs to evaluate the health and integrity of your graft during routine visits to catch any early signs of problems before they become serious. These scheduled check-ups are particularly important during the first year after transplantation, when rejection risk is highest, but they remain necessary for years afterward.^[2]

Patients at higher risk for rejection require even more careful monitoring. This includes people who have blood vessels growing into their cornea before transplant, those who have already experienced a previous graft rejection, children receiving transplants, or patients with large donor corneas. Additionally, individuals with other eye conditions such as glaucoma or problems with the eye surface need more frequent diagnostic assessments because these factors increase the chance of complications.^[1]

⚠️ Important

Understanding that rejection can occur months or even years after your transplant is crucial. The risk never completely disappears, although it tends to be highest in the first two years following surgery. Any sudden change in your vision or comfort should prompt an immediate visit to your eye care provider, as early treatment significantly improves the chances of saving the graft.

Classic Diagnostic Methods for Identifying Rejection

Diagnosing corneal graft rejection relies primarily on careful clinical examination by an eye care specialist. The cornerstone of diagnosis is the slit lamp examination, which is a specialized microscope that allows the doctor to view the structures of your eye in great detail. During this examination, your doctor uses a bright beam of light to illuminate the cornea and examine it under magnification. This non-invasive procedure causes no discomfort and provides detailed information about the health of your transplanted tissue.^[13]

During the slit lamp examination, your doctor looks for specific signs that distinguish rejection from other causes of graft problems. One of the most characteristic findings is corneal edema, which means swelling of the cornea that makes it appear cloudy or hazy. The transplanted cornea should normally be clear and transparent, so any cloudiness raises concern. Your doctor will also look for keratic precipitates, which are collections of white blood cells that appear as small white dots on the inner surface of the cornea. These deposits specifically on the donor tissue rather than on the surrounding host tissue strongly suggest rejection is occurring.^[13]

Another hallmark sign that doctors search for is called a Khodadoust line, also known as an endothelial rejection line. This appears as a distinct line on the cornea where you can see a clear boundary between swollen, cloudy cornea and normal, clear tissue. This line consists of inflammatory cells moving across the inner layer of the cornea and represents an active rejection episode. Finding this line is considered definitive evidence of endothelial rejection, which affects the critical inner cell layer of the cornea responsible for keeping it clear.^[13]

The examination also includes checking for inflammation in the front chamber of the eye, called anterior chamber reaction. Your doctor looks for signs of inflammatory cells floating in the fluid that fills the space between the cornea and the iris. Additionally, the doctor examines the blood vessels around the edge of the cornea, as engorgement or swelling of these vessels often accompanies rejection episodes.^[2]

Different types of rejection affect different layers of the cornea, and each has distinct diagnostic features. Epithelial rejection affects the outermost layer and appears as an elevated line or ridge at the edge of the graft that stains with fluorescein dye, which is a special orange dye placed in the eye that glows under blue light. This type is less common and may resolve on its own in some cases, but it signals that the immune system has recognized the donor tissue.^[13]

Stromal rejection affects the middle layer of the cornea and can appear as whitish infiltrates beneath the surface. These infiltrates may look similar to those seen in viral eye infections, which makes accurate diagnosis important to avoid confusion with other conditions. Sometimes stromal rejection presents with subepithelial infiltrates that resemble viral conjunctivitis, so your doctor must carefully distinguish between these possibilities.^[13]

The most serious and common form is endothelial rejection, which occurs in up to half of all rejection cases. This type affects the innermost layer of cells that pump fluid out of the cornea to keep it clear. Because human endothelial cells cannot regenerate or replace themselves through division, any loss of these cells is permanent. This makes endothelial rejection particularly dangerous for long-term graft survival. During examination, your doctor looks for corneal swelling, keratic precipitates, anterior chamber inflammation, and the characteristic Khodadoust line to diagnose this type.^[1]^[13]

Your eye care provider will also measure your visual acuity, which means testing how well you can see. A decrease in vision is one of the most common symptoms that brings patients in for evaluation. The doctor will compare your current vision to previous measurements to determine if there has been a change. They will also measure your intraocular pressure, which is the pressure inside the eye, because rejection can sometimes cause pressure changes that need monitoring and treatment.^[8]

Distinguishing rejection from other causes of graft failure is an essential part of diagnosis. Graft failure is a broader term that describes any reason the transplant stops functioning and becomes cloudy, which could result from multiple causes including rejection, infection, failure of the endothelial cell pump unrelated to rejection, or problems with the surface of the eye. Graft rejection specifically refers to the immune system attacking the donor tissue. This distinction matters because rejection requires specific immune-suppressing treatment, while other causes of graft failure need different approaches.^[13]

In some cases, doctors categorize endothelial rejection into three levels based on the severity of clinical findings: possible rejection, probable rejection, and definite rejection. This grading system helps guide treatment intensity and provides a framework for monitoring response to therapy. Definite rejection shows all the classic signs including keratic precipitates, corneal edema, and anterior chamber inflammation, while possible rejection might show only one or two findings.^[13]

Diagnostics for Clinical Trial Qualification

Clinical trials investigating new treatments for corneal graft rejection require standardized diagnostic criteria to ensure that all participants truly have the condition being studied. These trials typically use the same clinical examination methods described above but apply them with strict protocols to maintain consistency across different testing sites and examiners.

For enrollment in clinical trials, patients must undergo comprehensive slit lamp examination performed by experienced corneal specialists who document all findings in detail. The presence of specific diagnostic signs such as keratic precipitates, corneal edema, and rejection lines must be confirmed and photographed when possible. Trials often require that multiple clinical features be present simultaneously to confirm the diagnosis with certainty before including a patient in the study.^[1]

Visual acuity measurements are standardized in clinical trials, typically using specific charts and testing protocols that allow accurate comparison between different time points and different patients. Baseline visual acuity before treatment begins is carefully documented, as improvement or stabilization of vision serves as one of the primary outcome measures for determining if an experimental treatment is effective.

Trials may also include specialized imaging techniques to document the state of the graft. These can include photography of the cornea using the slit lamp camera, which creates permanent records of the graft appearance that can be reviewed by multiple experts. Some studies use advanced imaging technologies to measure corneal thickness or to count the number of endothelial cells remaining, although these are primarily research tools rather than routine diagnostic tests.

The timing of diagnosis is often important for clinical trial enrollment. Many studies specifically look at patients who present within a certain window after the onset of rejection symptoms, such as within the first eight days. This is because earlier treatment tends to be more successful, and trials want to test interventions when they are most likely to make a difference. Patients who have had rejection episodes lasting longer may not be eligible for certain trials.^[7]

Clinical trials also carefully document risk factors that might affect outcomes. This includes recording whether the patient has high-risk features such as corneal blood vessel growth, previous rejection episodes, or other eye conditions. The type of corneal transplant the patient received is documented, as different procedures like full-thickness penetrating keratoplasty versus partial thickness transplants have different rejection rates and may respond differently to treatments.^[2]

Intraocular pressure monitoring is particularly important in clinical trials testing steroid medications, since these drugs can cause pressure elevation as a side effect. Baseline pressure must be measured before treatment begins, and then monitored regularly throughout the trial to detect any medication-related complications.^[7]

⚠️ Important

Participation in clinical trials requires commitment to frequent follow-up visits and detailed examinations. However, these trials offer access to potentially better treatments and contribute valuable knowledge that may help future transplant patients. If you experience graft rejection, discussing clinical trial options with your eye care specialist may be worthwhile.

Prognosis and Survival Rate

Prognosis

The outlook following a corneal graft depends heavily on whether the patient has risk factors for rejection and how quickly treatment begins if rejection occurs. For first-time graft recipients who have no blood vessels in their corneal bed before surgery, the prognosis is quite favorable, with two-year survival rates exceeding 90 percent. However, this decreases substantially to between 35 and 70 percent in recipients with high-risk factors such as existing corneal blood vessels or previous graft rejections.^[1]

When rejection episodes do occur, approximately one-third of affected grafts will ultimately fail within six months despite treatment. The critical factor determining long-term success is whether the endothelial cells that keep the cornea clear can be preserved. Because these cells cannot regenerate themselves, any significant loss during rejection leads to permanent clouding of the cornea. Patients who respond quickly to treatment have better chances of maintaining graft clarity than those whose rejection episodes are more severe or prolonged.^[13]

The type of rejection also influences prognosis. Epithelial rejection affecting the surface layer may sometimes resolve on its own or with relatively mild treatment, and rarely progresses to complete graft failure. Stromal rejection affecting the middle layer is also less likely to cause complete failure if treated appropriately. However, endothelial rejection represents the most serious threat because it directly damages the cells responsible for corneal transparency. Even if an endothelial rejection episode is successfully reversed with treatment, the graft may still fail months or years later due to the permanent loss of endothelial cells that occurred during the rejection.^[1]^[13]

Survival rate

Overall long-term graft survival statistics vary depending on the specific type of transplant and patient characteristics. For standard full-thickness penetrating keratoplasty, published data shows long-term graft survival rates ranging from 52 to 99 percent, with this wide range reflecting differences in patient populations and follow-up periods. One major study found that at five years after surgery, 23 percent of patients had experienced at least one rejection event, and among those who had rejection, 37 percent experienced graft failure.^[2]

Studies of large numbers of patients show rejection rates between 14 and 34 percent following penetrating keratoplasty, with graft survival rates around 73 to 74 percent in some series. Newer techniques of partial thickness corneal transplantation generally show better outcomes, with lower rejection rates. Deep anterior lamellar keratoplasty, which replaces only the front layers while preserving the patient’s own endothelial cells, shows success rates from 77 to 99 percent with rejection rates between 6 and 20 percent. Endothelial transplant procedures also tend to have lower rejection rates compared to full-thickness transplants.^[2]

The prognosis worsens with each subsequent transplant if a graft fails and requires replacement. Second grafts have lower success rates than first grafts, and the survival rates for third and fourth repeat grafts drop to only 25 percent and 0 percent respectively in some studies. This progressive decline in success emphasizes the critical importance of preventing and treating rejection effectively in the initial graft.^[11]

One-year graft acceptance rates can be quite high at 86 percent, but the fifteen-year acceptance rate declines to 55 percent, showing that rejection remains a risk many years after transplantation. This long-term attrition rate is similar to survival statistics for other types of organ transplants, despite the cornea’s immune-privileged status.^[8]

#1 Clinical Trials Search in Europe